Watch: Biotech Going Up Against Big Pharma

As co-founder, chairman & chief executive of Ocugen, Shankar Musunuri, is looking to bring eye disease products to the patients that big pharma’s drugs have left out. The Malvern, Penn.-based company has four compounds in its pipeline at various stages of development. It’s most advanced candidate, OCU300, is gearing up for Phase III trials in 2018. It’s second candidate, OCU310, combines brimonidine, a drug usually designed for patients with glaucoma, and a steroid. With some of Ocugen’s products, like it’s OCU100 compound designed to delay the progression of retinitis pigmentosa, there is no other drug currently on the market – so there’s no immediate competition. “The goal is to get something to the market to help patients as soon as possible because they don’t have anything today,”

Follow us on social media for the latest updates in B2B!

Image

Latest

employer-sponsored apprenticeships
The Degree That Pays You Back: How Employer-Sponsored Apprenticeships Are Rewriting Higher Ed
March 9, 2026

Higher education is under pressure. Over the past few years, public confidence in the value of a four-year degree has declined significantly, with fewer Americans expressing a strong belief that traditional higher education delivers a worthwhile return on investment. At the same time, employers consistently report that graduates lack job-ready skills—particularly the “durable skills”…

Read More
Denial Data
Turning Denial Data Into Action: How Healthcare Organizations Can Fight Back Against Payer Denials
March 5, 2026

Healthcare providers across the U.S. are facing a growing wave of claim denials that is putting pressure on already strained hospital finances. Industry research from the American Hospital Association shows that nearly 15% of medical claims submitted to private payers are initially denied, forcing hospitals and health systems to spend about $19.7 billion annually attempting…

Read More
Jabra
ISE 2026: Jabra Unveils Scalable Room Solutions for the Hybrid Workplace
March 5, 2026

At ISE 2026, Jabra highlighted how meeting technology is evolving to support the realities of hybrid work, where the experience must be equally effective for people inside and outside the room. In a conversation with Craig Durr, Chief Analyst and Founder of The Collab Collective, Jabra’s VP of Video Product Olly Henderson explained that…

Read More
Marketing AI Pulse
The Marketing AI Pulse Brief for Feb 2026: Trust in the World of LLM Ads, OpenClaw, Reddit & More!
March 3, 2026

Starting in 2026, The Marketing AI SparkCast alternates between the Marketing AI Pulse Monthly Brief and in-depth interviews with leading marketing AI innovators. This episode is the February 2026 edition of the Monthly Brief and focuses on trust and authenticity in an AI-driven world. Aby Varma and Matt Cyr explore the emergence of advertising inside…

Read More